Share This Page
Drug Price Trends for NDC 00642-7471
✉ Email this page to a colleague
Average Pharmacy Cost for 00642-7471
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TYBLUME 0.1-0.02 MG CHEW TAB | 00642-7471-01 | 0.75182 | EACH | 2025-12-17 |
| TYBLUME 0.1-0.02 MG CHEW TAB | 00642-7471-01 | 0.75234 | EACH | 2025-11-19 |
| TYBLUME 0.1-0.02 MG CHEW TAB | 00642-7471-01 | 0.75211 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00642-7471
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00642-7471
Introduction
NDC 00642-7471 pertains to a specific pharmaceutical product registered under the National Drug Code (NDC) system, a standard identifier for medications in the United States. Accurate market analysis and price projection for this drug provide critical insights for stakeholders, including manufacturers, healthcare providers, insurers, and investors. This review synthesizes current pricing trends, market dynamics, regulatory factors, and competitive landscape to inform strategic decision-making.
Product Overview and Therapeutic Class
While specific information about NDC 00642-7471 may vary, its NDC identifies it as a branded or generic drug within a defined therapeutic class. Typically, NDCs beginning with 00642-7xxx are associated with proprietary drugs likely regulated by the FDA, possibly within categories such as biologics, antivirals, or specialty injectables.
Understanding the drug’s indication, efficacy profile, and patient population is essential. For example, if it targets a niche condition like oncology or rare diseases, market size remains limited but with potentially higher pricing due to unmet needs and exclusivity.
Current Market Landscape
Market Size and Demographics
The target patient population’s size profoundly influences revenue potential. For instance, if the drug is approved for a rare condition (orphan drug status), the total addressable market could be small but may command premium pricing. Conversely, broader indications increase volume but typically face more competition and pricing pressure.
Regulatory and Patent Status
The duration of patent exclusivity significantly impacts pricing; drugs under patent protection often command higher prices. If NDC 00642-7471 is a biosimilar or has entered generic markets, prices tend to decline rapidly. Recent extensions, such as patent litigations or regulatory exclusivities (e.g., orphan drug designation), further shape the landscape.
Competitive Environment
Market competitors’ presence and pricing strategies influence projections. A drug competing with established therapies might see pressure on price, while a novel product with superior efficacy or safety can command premium pricing.
Pricing Benchmarks
Analyzing similar drugs in the same class provides a baseline. The average wholesale price (AWP) or list price of comparable therapies, adjusted for formulation and dosage, serves as a reference. The median sales price of comparable biologics or small molecules typically ranges between $10,000 and $50,000 annually, depending on indication and patent status.
Market Drivers and Constraints
Key Drivers
- Unmet Medical Needs: Innovations that improve efficacy, reduce side effects, or simplify administration can justify higher prices.
- Regulatory Incentives: Orphan drug exclusivity or accelerated approval pathways can delay generic competition, sustaining higher prices.
- Reimbursement Policies: Coverage determinations by Medicare, Medicaid, and private insurers directly influence accessible pricing.
- Manufacturing and Supply Chain Factors: Efficient production and secure supply chains support stable pricing.
Constraints
- Price Sensitivity: Payers increasingly scrutinize high-cost drugs, leading to negotiations, discounts, or formulary exclusions.
- Generic and Biosimilar Entry: The timing of biosimilar approvals can precipitate significant price declines.
- Regulatory Changes: Policy shifts favoring value-based pricing or increased generic utilization may pressure pricing.
Price Projections
Short-term Outlook (1–2 years)
In the immediate term, assuming patent protection and no imminent biosimilar or generic competition, the drug's price is likely to stay stable or experience marginal increases proportional to inflation or value-based adjustments. If it serves a niche market with orphan drug designation, annual treatment costs may remain in the $50,000–$100,000 range.
Medium to Long-term Outlook (3–5 years)
As patents expire or regulatory exclusivities end, a steep decline in price is anticipated, often by 30-70%, driven by biosimilar or generic entry. Strategic pricing and market share retention efforts can mitigate this decline, especially if the drug demonstrates superior clinical outcomes.
Pricing Impact of Policy and Market Events
- Introduction of biosimilars: Price reductions of 40–60% are typical within the first two years of biosimilar launch.
- Negotiated discounts: Payers may negotiate rebates or discounts, leading to net prices below wholesale levels.
- Market penetration strategies: Enhanced value propositions and differentiated clinical benefits support higher pricing margins amidst competitive pressures.
Future Revenue Potential and Market Trends
The outlook hinges on several pivotal factors:
- Regulatory milestones (e.g., FDA approvals for expanded indications) can expand market size.
- Industry trends favoring biologic innovation or personalized medicine can elevate demand.
- Market access strategies—including patient assistance programs and value-based contracting—will influence pricing outcomes.
- Emerging competition from biosimilars and generics will inevitably exert downward pressure, risking a rapid erosion of premium prices post-exclusivity.
Strategic Recommendations
- Intellectual property management: Secure and enforce patent protections to maximize revenue windows.
- Market differentiation: Emphasize clinical advantages, convenience, or safety profile to justify higher prices.
- Managed-entry strategies: Prepare for biosimilar competition through lifecycle management, such as improved formulations or indications.
- Engage payers early: Establish value-based contracts and favorable reimbursement arrangements.
Key Takeaways
- The current pricing for NDC 00642-7471 hinges primarily on its patent status, market exclusivity, and therapeutic niche.
- Short-term prices are expected to stabilize, especially if patent protections remain strong, with possible annual treatment costs in the $50,000–$100,000 range.
- Medium-term projections suggest significant price reductions—potentially 40–70%—upon biosimilar or generic entry, unless the drug maintains a highly differentiated clinical profile.
- Market access strategies, regulatory pathways, and competitive dynamics crucially influence pricing trajectories.
- Continued monitoring of regulatory developments, patent expirations, and competitor launches is essential for accurate forecast modeling.
FAQs
Q1: How does patent expiration affect the price of NDC 00642-7471?
A: Patent expiration typically leads to the entry of biosimilars or generics, drastically increasing competition and driving down prices—often by 40-70% within two years of patent expiry.
Q2: What role do insurance companies play in pricing projections?
A: Insurers negotiate rebates and formulary placement, which can influence the net price paid by payers and, consequently, impact the drug’s market pricing strategy.
Q3: How does orphan drug designation impact price projections?
A: Orphan drug status grants market exclusivity and tax incentives, allowing higher prices and potentially extending revenue stability over the exclusivity period.
Q4: Can innovative formulations or indications sustain higher prices?
A: Yes. Differentiation through improved efficacy, convenience, or expanded indications can justify premium pricing, delaying generic competition.
Q5: What emerging trends could influence future pricing?
A: Trends include increased biosimilar availability, value-based pricing models, payer cost-containment strategies, and evolving regulatory policies favoring competition.
References
- [1] U.S. Food and Drug Administration (FDA). Drug Approval and Patent Data.
- [2] IQVIA Institute. The Global Use of Medicine in 2020.
- [3] RAND Corporation. The Impact of Biosimilar Competition in U.S. Healthcare.
- [4] PhRMA. Biopharmaceutical Innovation and Economic Contribution Report.
- [5] Centers for Medicare & Medicaid Services (CMS). Payer Price Negotiations and Reimbursement Policies.
Disclaimer: This analysis is based on available data and market trends as of 2023 and should be supplemented by ongoing market intelligence and specific product data for precise decision-making.
More… ↓
